Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th ...
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102Phase ...